Technical Field
Examples disclosed herein relate generally to the detection of cardiac function in a patient, and more particularly to the detection of cardiac function and the treatment of cardiac conditions in an ambulatory medical device, such as a wearable defibrillator.
Discussion
With a wearable defibrillator worn by an ambulatory patient, the patient's electrocardiogram (ECG) signal is obtained from body surface electrodes. Determining the true characteristics of an ambulatory patient's cardiac cycle based on an ECG signal in this manner can be difficult. Electrical noise and electrode fall-off frequently degrade the quality of the ECG signal. In addition, the characteristics of ECG signals vary from patient to patient due to factors such as the patient's state of health, individual physiology, and electrode positions on the body surface.
Known ambulatory wearable defibrillators, such as the LifeVest® Wearable Cardioverter Defibrillator available from Zoll Medical Corporation of Chelmsford, Mass., use four ECG sensing electrodes in a dual-channel configuration. That is, an electrical signal provided by one of the four ECG sensing electrodes is paired with the electrical signal provided by another of the four ECG sensing electrodes to form a channel. This arrangement of ECG sensing electrodes is usually suitable because in most cases it is rare that noise or electrode movement affects the entire body circumference. The dual-channel configuration provides redundancy and allows the system to operate on a single channel if necessary. Because signal quality also varies from patient to patient, having two channels provides the opportunity to have improved signal pickup, since the ECG sensing electrodes are located in different body positions.
Examples disclosed herein are directed to a wearable medical device that monitors ECG signals received on a plurality of channels and interprets the ECG signals according to a set of preferences. This set of preferences indicates which channels and detection methods are more likely to provide accurate results for the patient wearing the wearable medical device. By interpreting ECG signals according to the set of preferences, the wearable medical device decreases the frequency of falsely detected cardiac malfunctions.
According to one example, an ambulatory medical device is provided. The device includes a plurality of electrodes disposed at spaced apart positions about a patient's body and a control unit. The control unit includes a sensor interface coupled to the plurality of electrodes and configured to receive a first ECG signal from a first pairing of the plurality of electrodes and to receive a second ECG signal from a second pairing of the plurality of electrodes, a memory storing information indicating a preferred pairing, the preferred pairing being either the first pairing or the second pairing and a processor coupled to the sensor interface and the memory and configured to resolve conflicts between interpretations of first ECG signal and the second ECG signal in favor of the preferred pairing. In some examples, the first pairing includes electrodes that are distinct from the electrodes included in the second pairing. In other examples, one of the plurality of electrodes is common between the first and second pairings. The device may include a plurality of electrodes that are integrated into a garment that is worn about a patient's body. In addition, the interpretations of the ECG signals may detect heartbeats.
According to another example, a method of monitoring ECG signals is provided. In some examples, the method is executed by an ambulatory medical device as described herein. The method includes acts of determining a first interpretation of a first ECG signal provided by a first channel of the plurality of channels, determining a second interpretation of a second ECG signal provided by a second channel of the plurality of channels, determining which one of the first channel and the second channel provides a more reliable ECG signal and resolving a conflict between the first interpretation and the second interpretation based upon which of the first channel and the second channel is determined to provide the more reliable ECG signal.
According to at least one example, an ambulatory medical device is provided. The device includes a plurality of electrodes disposed at spaced apart positions about a patient's body and a control unit. The control unit includes a sensor interface, a memory and a processor. The sensor interface is coupled to the plurality of electrodes and configured to receive a first ECG signal from a first pairing of the plurality of electrodes and to receive a second ECG signal from a second pairing of the plurality of electrodes. The memory stores information indicating a preferred pairing, the preferred pairing being either the first pairing or the second pairing. The processor is coupled to the sensor interface and the memory and is configured to resolve conflicts between interpretations of first ECG signal and the second ECG signal in favor of the preferred pairing.
The device may further comprise a garment that is configured to be worn about the patient's body. The plurality of electrodes may be integrated into the garment. The plurality of electrodes may include adhesive electrodes. In some examples, the interpretations of the ECG signals may detect heartbeats.
In the device, the information indicating the preferred pairing may include information indicating a first heart rate detection method preferred for the first pairing and a second heart rate detection method preferred for the second pairing. The processor may be further configured to interpret the first ECG signal using the first heart rate detection method and interpret the second ECG signal using the second heart rate detection method.
In the device, the processor may be further configured to determine a first confidence level for the first pairing, determine a second confidence level for the second pairing, determine the preferred pairing with reference to the first confidence level and the second confidence level and store the information indicating the preferred pairing in the memory. In addition, the processor may be configured to determine the first confidence level by comparing the first ECG signal to benchmark information. The benchmark information may reflect a particular patient's normal rhythm. In addition, the processor may be configured to compare the first ECG signal to the benchmark information by comparing a morphology of the first ECG signal to a morphology indicated within the benchmark information.
According to another example, a method of monitoring ECG signals using an ambulatory medical device is provided. The method includes acts of receiving, by the ambulatory medical device, a first ECG signal from a first pairing of a plurality of electrodes, receiving a second ECG signal from a second pairing of the plurality of electrodes and resolving conflicts between interpretations of first ECG signal and the second ECG signal in favor of a preferred pairing being either the first paring or the second pairing.
In the method, the act of resolving the conflicts between the interpretations may include resolving conflicts between interpretations that detect heartbeats. The method may further comprise acts of interpreting the first ECG signal using a first heart rate detection method and interpreting the second ECG signal using a second heart rate detection method. The first heart rate detection method may be different from the second heart rate detection method.
The method may further comprise acts of determining a first confidence level for the first pairing, determining a second confidence level for the second pairing and determining the preferred pairing with reference to the first confidence level and the second confidence level. In the method, the act of determining the first confidence level may include an act of comparing the first ECG signal to benchmark information. The act of comparing the first ECG signal to the benchmark information may include comparing the first ECG signal to benchmark information that reflects a particular patient's normal rhythm. In addition, the act of comparing the first ECG signal to the benchmark information may include comparing a morphology of the first ECG signal to a morphology indicated within the benchmark information.
In another example, a non-transitory computer readable medium having stored thereon sequences of instruction for monitoring ECG signals is provided. The instructions instruct at least one processor to receive a first ECG signal from a first pairing of the plurality of electrodes, receive a second ECG signal from a second pairing of the plurality of electrodes and resolve conflicts between interpretations of first ECG signal and the second ECG signal in favor of a preferred pairing being either the first pairing or the second pairing.
Furthermore, the instructions may further instruct the at least one processor to determine a first confidence level for the first pairing, determine a second confidence level for the second pairing and determine the preferred pairing with reference to the first confidence level and the second confidence level. The instructions that instruct the at least one processor to determine the first confidence level may include instructions that instruct the at least one processor to compare the first ECG signal to benchmark information. The instructions that instruct the at least one processor to compare the first ECG signal to the benchmark information may include instructions that instruct the at least one processor to compare a morphology of the first ECG signal to a morphology indicated within the benchmark information.
Still other aspects, examples, and advantages of these exemplary aspects and examples, are discussed in detail below. Moreover, it is to be understood that both the foregoing information and the following detailed description are merely illustrative examples of various aspects, and are intended to provide an overview or framework for understanding the nature and character of the claimed subject matter. References to “an example,” “some examples,” “an alternate example,” “various examples,” “one example,” “at least one example,” “this and other examples” or the like are not necessarily mutually exclusive and are intended to indicate that a particular feature, structure, or characteristic described in connection with the example may be included in that example and other examples. The appearances of such terms herein are not necessarily all referring to the same example.
Furthermore, in the event of inconsistent usages of terms between this document and documents incorporate herein by reference, the term usage in the incorporated references is supplementary to that of this document; for irreconcilable inconsistencies, the term usage in this document controls. In addition, the accompanying drawings are included to provide illustration and a further understanding of the various aspects and examples, and are incorporated in and constitute a part of this specification. The drawings, together with the remainder of the specification, serve to explain principles and operations of the described and claimed aspects and examples.
The accompanying drawings are not intended to be drawn to scale. In the drawings, components that are identical or nearly identical may be represented by a like numeral. For purposes of clarity, not every component is labeled in every drawing. In the drawings:
Examples disclosed herein manifest an appreciation that some patients regularly produce ECG signals that are highly idiosyncratic. In these instances, the electrical signals generated during these patient's cardiac cycles can cause conventional heart rate detection methods to detect an erroneous number of heartbeats over a given period of time. These errors are particularly problematic to a wearable medical device, such as a wearable defibrillator, because, within this context, a real-time determination of heart rate can be matter of life and death importance. For this reason, wearable medical devices that monitor heart rate tend to interpret ECG signals in a conservative light and err on the side of reporting potential arrhythmias or other cardiac malfunction to a patient, physician or others. An unfortunate side-effect of this approach is that, in some instances, patients are forced to regularly deal with falsely indicated cardiac malfunction.
The conventional heart rate detection methods mentioned above include derivative-based QRS detectors that detect heartbeats by identifying QRS complexes, which are representative of ventricular depolarization, within an ECG signal. Conventional derivative-based QRS detectors identify QRS complexes by comparing a slope of the ECG signal to established thresholds. For example, a conventional derivative-based QRS detector may compare a magnitude of the slope of the R wave portion of the QRS complex to a threshold, and if the magnitude exceeds the threshold, the QRS detector may indicate the occurrence of a heartbeat. Typically, such derivative-based QRS detectors are configured (via hardware or software) to the morphology of the heart, and the patient.
For instance, to prevent over counting, the QRS detector may be configured to detect an occurrence of a QRS complex only after a minimum amount of time has transpired after a prior QRS complex. In some examples this minimum amount of time, which is referred to herein as the “refractory period” or the “programmed refractory period,” is typically configured to be about 200 milliseconds. Moreover, the QRS detector may also be configured to use an adaptive threshold that is based upon prior samples of the patient's ECG signal, to account for variations from one patient to another, or to changes in the patient's medical condition. Upon identifying a QRS complex in this manner, conventional derivative-based QRS detectors indicate the occurrence of a heartbeat.
Given their reliance on slope, conventional derivative-based QRS detectors may double count heartbeats where a patient's normal rhythm presents an elongated QRS complex or an abnormally sharp T wave. For example, if the QRS complex generated by the patient's normal rhythm has a duration that exceeds the configured refractory period of the QRS detector, the QRS detector may detect a heartbeat at the beginning of the QRS complex and, after the refractory period has expired, detect another heartbeat near the end of the QRS complex. In another example, if the amplitude of the ECG signal is small, the adaptive thresholds used by the QRS detector may adjust to low values. In this situation, even a moderate spike in one of the other waves, such as the T wave, that occurs after expiration of the refractory period may result in a slope steep enough to cause the QRS detector to indicate the occurrence of a false heartbeat.
To address these difficulties, some exemplary wearable medical devices disclosed herein process ECG signals from multiple channels according to a set of preference information that is tailored to fit the characteristics of the patient wearing the wearable medical device. The set of preference information may include, among other information, information indicating preferred channels and rate detection methods for the patient. For instance, in at least one example, a wearable medical device processes ECG signals received via two channels, namely a front to back channel and a side to side channel, using one or more QRS rate detectors, which may include, for example, one or more conventional QRS rate detectors. According to this example, the wearable medical device resolves conflicts between these two channels in favor of a previously identified, preferred channel. Further, in some examples, the set of preference information is automatically configured by the wearable medical device and continuously adjusted during its operation. For example, the set of preference information may be adjusted based on the current health of the patient, the activity of the patient, and the present locations of the electrodes relative to the patient's body.
The examples of the processes and apparatuses described herein are not limited in application to the details of construction and the arrangement of components set forth in the following description or illustrated in the accompanying drawings. The methods and apparatuses are capable of implementation in other examples and of being practiced or of being carried out in various ways. Examples of specific implementations are provided herein for illustrative purposes only and are not intended to be limiting. In particular, acts, elements and features discussed in connection with any one or more examples are not intended to be excluded from a similar role in any other examples.
Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. Any references to examples or elements or acts of the systems and methods herein referred to in the singular may also embrace examples including a plurality of these elements, and any references in plural to any example or element or act herein may also embrace examples including only a single element. References in the singular or plural form are not intended to limit the presently disclosed systems or methods, their components, acts, or elements. The use herein of “including,” “comprising,” “having,” “containing,” “involving,” and variations thereof is meant to encompass the items listed thereafter and equivalents thereof as well as additional items. References to “or” may be construed as inclusive so that any terms described using “or” may indicate any of a single, more than one, and all of the described terms.
Electrode System
U.S. Pat. No. 8,706,215, titled “WEARABLE AMBULATORY MEDICAL DEVICE WITH MULTIPLE SENSING ELECTRODES,” issued Apr. 22, 2014 (hereinafter the “'215 patent”), which is incorporated by reference herein in its entirety, describes an apparatus and method for processing ECG signals using one or more channels. With reference to FIGS. 1A and 1B, the '215 patent discloses an electrode system 100 that incorporates a control unit 30. As described with reference to FIG. 4 in the '215 patent, at least one example of the control unit 30 includes a processor 410, data storage 412, a sensor interface 414, a therapy delivery interface 416, a user interface 418 and a battery 420.
Some of the examples disclosed herein for processing ECG signals according to a set of preferences are implemented using the electrode system 100 disclosed in the '215 patent.
The cardiac function analyzer 102 is configured to analyze a portion of the ECG signal to configure preference information, such as the preference information 104, and to determine cardiac functions of the patient using the preference information. The cardiac function analyzer 102 may be implemented using hardware or a combination of hardware and software. For instance, in one example, the cardiac function analyzer 102 is implemented as a software component that is stored within the data storage 412 and executed by the processor 410. In this example, the instructions included in the cardiac function analyzer 102 program the processor 410 to configure preference information and determine the heart rate of the patient using the preference information. In other examples, the cardiac function analyzer 102 may be an application-specific integrated circuit (ASIC) that is coupled to the sensor interface 414 and tailored to determine the heart rate of the patient. Thus, examples of the cardiac function analyzer 102 are not limited to a particular hardware or software implementation. In addition, particular examples of the processes that the cardiac function analyzer 102 is configured to perform are discussed further below with reference to
The preference information 104 includes data that describes parameters used by the cardiac function analyzer 102 during its analysis of ECG signals. More particularly, according to the illustrated example, the preference information 104 identifies one or more channels from which the cardiac function analyzer 102 receives ECG signals. In this example, the preference information 104 also includes information that ranks each channel relative to the other identified channels. As is discussed further below, the cardiac function analyzer 102 uses this ranking information to resolve conflicts generated from the interpretation of two or more ECG signals received via the identified channels.
In some examples, the preference information 104 also includes information indicating one or more preferred rate detectors for each channel. In these examples, the cardiac function analyzer 102 uses the preferred rate detectors of each channel to interpret the ECG signal received from each channel. In other examples, the preference information 104 includes an association that groups channel and rate detector preference information into individual profiles. In these examples, the preference information 104 also includes data that indicates an active profile that is used by the cardiac function analyzer 102 to analyze ECG signals. These examples provide the added advantage of easily configuring channel and rate detector information preferences simply by changing the indicator of the active profile from the active profile to another profile.
The preference information 104 may be stored in any logical construction capable of storing information on a computer readable medium including, among other structures, flat files, indexed files, hierarchical databases, relational databases or object oriented databases. In addition, various examples organize the preference information 104 into particularized and, in some cases, unique structures to perform the functions disclosed herein. In these examples, the data structures are sized and arranged to store values for particular types of data.
In some examples, the components disclosed herein, such as the cardiac function analyzer 102, may read parameters that affect the functions performed by the components. These parameters may be physically stored in any form of suitable memory including volatile memory, such as RAM, or nonvolatile memory, such as a magnetic hard drive. In addition, the parameters may be logically stored in a propriety data structure, such as a database or file defined by a user mode application, or in a commonly shared data structure, such as an application registry that is defined by an operating system. In addition, some examples provide for both system and user interfaces, as may be implemented using the user interface 418, that allow external entities to modify the parameters and thereby configure the behavior of the components.
Preferential ECG Signal Processing
In act 204, an electrode system, such as the electrode system 100 discussed above, receives one or more ECG signals via one or more channels. According to one example, the electrode system receives ECG signals from a front-to-back channel and from a side-to-side channel. The front-to-back channel includes an electrode positioned on the chest of the patient and another electrode positioned on the back of the patient. The side-to-side channel includes an electrode positioned on the left side of the chest and another electrode positioned on the right side of the patient. Other examples may employ additional, or fewer, electrodes or electrodes located in other positions on the patient's body. In addition, act 204 may include a variety of acts designed to render an accurate interpretation of the ECG signal. For instance, in one example, a control unit, such as the control unit 30 discussed above with reference to
In act 206, the filtered ECG signals are analyzed to determine a confidence level for the interpretation of each filtered ECG signal. According to the illustrated example, the filtered ECG signal of each channel is compared to benchmark information to determine a level of confidence that interpretations of the filtered ECG signal are accurate. As discussed further below, this benchmark information may include benchmark ECG signals and benchmark values that characterize attributes of a normal cardiac cycle.
The source of the benchmark information varies from example to example. For instance, according to one example, a standardized representation of a normal sinus rhythm, such as the ECG signal illustrated in
Like the source of the benchmark ECG signal, the comparison operation used within the act 206 to determine the quality of interpretations of the filtered ECG signals varies between examples. In some examples, the morphology of the filtered ECG signal is compared to the morphology of the benchmark ECG signal. In these examples, the level of confidence associated with the channel that received the filtered ECG signal is directly related to the fit of the filtered ECG signal to the benchmark ECG signal. More particularly, according to one example, a full cardiac cycle that includes P, Q, R, S and T waves is interpreted from the filtered signal. In this example, a deviation from the interpreted benchmark wave sequence of P, Q, R, S and T waves, such as one or more repeated R waves, indicates a potential double counting of a heartbeat and results in a decreased level of confidence associated with the channel. In some examples, this comparison operation is conducted by a user, such as a physician, through visual inspection.
In another example, the heart rate detected by each combination of channel and heart rate detection method is compared to the actual heart rate as determined by a user, such as a physician. In this example, the heart rate detection methods used may include derivative-based QRS detectors, spectrum analyzers or axis analyzers, as described in commonly owned U.S. Pat. No. 5,944,669 (hereinafter referred to as the “'669 patent”), which is incorporated herein by reference in its entirety. In this example, the level of confidence associated with the channel receiving the filtered ECG signal is inversely related to any difference between the heart rate detected and the actual heart rate. In addition, a level of confidence for each combination of channel and heart rate detection method may be established using this example.
In other examples, the refractory period is automatically configured to more closely fit the duration of detected QRS complexes. According to these examples, a valid QRS complex is identified by matching the morphology of the benchmark ECG signal to the morphology of the filtered ECG signal. In these examples, the refractory period is adjusted (in most cases lengthened) to encompass the duration of the valid QRS complex while the morphology of the benchmark ECG signal continues to match the morphology of the filtered ECG signal. In at least one example, an axis analyzer, such as the axis analyzer described in the '669 patent, identifies the valid QRS complex and monitors the filtered ECG signal to ensure that a match between the filtered ECG signal and the benchmark ECG is maintained. Channels with refractory periods adjusted in this manner are associated with a high level of confidence.
In act 208, preferences are established for determining the cardiac function of a given patient. In one example, preference information, such as preference information 104, is stored within the data storage 412. This preference information includes a ranking of channels based on the results of the comparison performed in act 206 with channels having a higher level of confidence being ranked above channels with a lower level of confidence. In another example, the preference information also ranks heart rate detection methods by channel, with heart rate detection methods having a higher level of confidence being ranked above heart rate detection methods having a lower level of confidence. In other examples, the ranking information may include the strength of the fit detected between the filtered ECG signal and the benchmark ECG signal or the output of the axis analyzer. In some of these examples, the strength of the fit reflects any differences in timing between interpreted ECG signal characteristics, such as QRS complexes, and interpreted benchmark ECG signal characteristics. According to a variety of examples, act 208 can be repeated at periodic intervals or as requested by a user, such as a patient or a physician. The process 200 ends at 210.
Processes in accord with the process 200 configure an electrode system, such as the electrode system 100 discussed above, to include a set of preferences for processing ECG signals. According to some examples, the process 200 is conducted by an electrode system, such as the electrode system 100 discussed above. In these examples, the data storage 412 includes the benchmark information and the cardiac function analyzer 102 conducts the acts included in the process 200. In other examples, some aspects of the process 200 are conducted by users. For instance, in one example, a user, such as a physician, performs the act 206 by determining the confidence level associated with each channel and heart rate detection method and if the user notices that the amplitude or signal to noise ratio of a particular channel is superior, the confidence level associated with that channel is increased. Further, in this example, the user performs the act 208 by storing the preference information in the electrode system, via a user interface, such as the user interface 418.
According to another example, the user, such as a physician, performs the act 208 by causing the preference information to be stored on the control unit of an electrode system via a network interface. In this example, a processor included in the control unit of the electrode system, such as the processor 410 of the control unit 30, is coupled to a network interface such as the network interface 206 described in U.S. Pat. No. 8,904,214, titled “SYSTEM AND METHOD FOR CONSERVING POWER IN A MEDICAL DEVICE,” issued Dec. 2, 2014, which is incorporated by reference herein in its entirety.
In act 404, the cardiac function analyzer 102, discussed above, retrieves preference information, such as preference information 104 discussed above, from data storage. According to one example, the preference information includes information ranking the channels through which ECG signals can be received and further indicating a preferred set of ranked channels. In another example, the preference information includes information ranking the heart rate detection methods available for each ranked channel and indicating a preferred set of heart rate detection methods.
In act 406, the cardiac function analyzer 102 acquires ECG signals from each of the preferred set of ranked channels. The electrode system may perform a variety of acts designed to render an accurate interpretation of the ECG signal. For instance, in one example, a control unit, such as the control unit 30 discussed above with reference to
In act 408, the cardiac function analyzer 102 processes the ECG signals to determine a heart rate for the patient.
In act 504, the cardiac function analyzer 102 processes a portion of the filtered ECG signal received by each preferred channel using one or more of the heart rate detection methods discussed above with reference to the process 200. For instance, the cardiac function analyzer 102 may utilize conventional derivative-based QRS detectors, axis detectors or others. According to a particular example discussed further below, when the cardiac cycle appears to be in a normal sinus rhythm, the cardiac function analyzer 102 determines a heart rate using both a QRS detector and an axis detector. In this example, the axis detector indicates the occurrence of a heartbeat when a peak in the magnitude indicated by the axis detector corresponds to a zero phase crossing. In another example, the axis detector may concurrently compare the quality of the fit of multiple ECG signals coming from multiple channels to a benchmark ECG and may use the heart rate determined in this manner provided that the quality of the fit between the benchmark ECG signal and the multiple ECG signals meets a predetermined value. In still another example, a single channel fit is performed using the axis detector. In these examples that utilize an axis detector, the quality of the fit is determined by summing errors calculated between samples of the benchmark ECG signal and one or more ECG signals over an identified period.
In act 506, if the results of these methods agree (for example, if each method detects a single heartbeat from the portion of the interpreted ECG signal) then the cardiac function analyzer 102 proceeds to act 510. Otherwise, the cardiac function analyzer 102 proceeds to act 508. In act 508, the cardiac function analyzer 102 resolves conflicts between channels and heart rate detection methods. The particular conflict resolution procedure employed varies from example to example and examples are not limited to a particular approach to resolving conflicting results between channels or combinations of channels and heart rate detection methods. For instance, according to one example, the cardiac function analyzer 102 resolves conflicts that involve multiple channels in favor of the highest ranking preferred channel. In another example, the cardiac function analyzer 102 resolves conflicts that involve multiple channels and heart rate detectors in favor of the result indicated by a majority of the channel and heart rate detector combinations. Continuing with the particular example discussed above involving the QRS and axis detectors, conflicts between QRS detector results on separate channels are resolved in favor of the channel with a result that agrees with the axis detector result.
In act 510, if the all of the interpretations, or the favored interpretations, of the ECG signals indicate that a heartbeat has occurred, the cardiac function analyzer 102 records the occurrence of a heartbeat in act 512. Otherwise, the cardiac function analyzer 102 determines if an interruption in monitoring is about to commence, such as an interruption caused by shutdown of the electrode system, in act 514. If so, the cardiac function analyzer ends the process 500 at 516. Otherwise, the cardiac function analyzer 102 returns to act 504 and the process 500 continues.
Examples in accord with process 500 enable an electrode system to more accurately track patient heart rate. More accurate heart rate tracking results in several benefits. These benefits include more accurate patient historical information and generation of fewer falsely indicated arrhythmias. Fewer false arrhythmias, in turn, may result in avoidance of unnecessary alarms and delivery of therapy to a patient, thereby increasing the runtime between charges of the electrode system and avoiding unnecessary patient discomfort.
Each of the processes disclosed herein depicts one particular sequence of acts in a particular example. The acts included in each of these processes may be performed by, or using, an electrode system specially configured as discussed herein. Although described herein in association with an electrode system of a wearable defibrillator such as the LIFEVEST Cardioverter defibrillator, embodiments disclosed herein may be used with any electrode system, including conventional stick-on adhesive electrodes, dry capacitive ECG electrodes, radio transparent electrodes, etc. Some acts are optional and, as such, may be omitted in accord with one or more examples. Additionally, the order of acts can be altered, or other acts can be added, without departing from the scope of the systems and methods discussed herein. In addition, as discussed above, in at least one example, the acts are performed on a particular, specially configured machine, namely an electrode system configured according to the examples disclosed herein.
Usage Scenario
According to one example, a user, such as a physician, may perform act 206 of process 200 and thereby determine that the SS channel is susceptible to double counting by comparing the morphology of the ECG signal acquired via the SS channel to an ECG signal representative to a normal sinus rhythm. Further, the user may perform act 208 by configuring preference information to rank the FB channel higher than the SS channel. After receiving this preference information and during the execution of process 400, the exemplary electrode system favors the FB channel over the SS channel if the two channels yield differing heart rates. This approach results in a decreased likelihood of heartbeat double counting because the QRS complexes displayed within the FB channel do not extend beyond the programmed refractory period and are, therefore, less likely to be double counted.
Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the scope of the invention. Accordingly, the foregoing description and drawings are by way of example only.
This application claims the benefit under 35 U.S.C. § 120 as a continuation of U.S. application Ser. No. 14/536,189, titled “SELECTION OF OPTIMAL CHANNEL FOR RATE DETERMINATION,” filed on Nov. 7, 2014, now U.S. Pat. No. 9,408,548, issued Aug. 9, 2016, which maims the benefit under 35 U.S.C. § 120 as a continuation of U.S. application Ser. No. 13/428,329, titled “SELECTION OF OPTIMAL CHANNEL FOR RATE DETERMINATION,” filed on Mar. 23, 2012, now U.S. Pat. No. 8,897,860, issued Nov. 25, 2014, which claims priority under 35U.S.C. § 119(e) to U.S. Provisional Application Ser. No. 61/467,599, titled “SELECTION OF OPTIMAL CHANNEL FOR RATE DETERMINATION,” filed on Mar. 25, 2011, all of which are hereby incorporated herein by reference in their entireties for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
2688752 | Sbarra et al. | Sep 1954 | A |
3241556 | Zacouto | Mar 1966 | A |
3409007 | Fuller | Nov 1968 | A |
3460542 | Gemmer | Aug 1969 | A |
3553651 | Bird et al. | Jan 1971 | A |
3664560 | Perkins | May 1972 | A |
3702613 | Panico et al. | Nov 1972 | A |
3706313 | Milani et al. | Dec 1972 | A |
3724455 | Unger | Apr 1973 | A |
3744482 | Kaufman et al. | Jul 1973 | A |
3826245 | Funfstuck | Jul 1974 | A |
3862636 | Bell et al. | Jan 1975 | A |
3886950 | Ukkestad et al. | Jun 1975 | A |
3897785 | Barto, Jr. | Aug 1975 | A |
3942533 | Cannon, III | Mar 1976 | A |
3961623 | Milani et al. | Jun 1976 | A |
4002239 | Buchalter | Jan 1977 | A |
4088138 | Diack et al. | May 1978 | A |
4094310 | McEachern et al. | Jun 1978 | A |
4136690 | Anderson et al. | Jan 1979 | A |
4360030 | Citron | Nov 1982 | A |
4576170 | Bradley et al. | Mar 1986 | A |
4580572 | Granek et al. | Apr 1986 | A |
4583547 | Granek et al. | Apr 1986 | A |
4608987 | Mills | Sep 1986 | A |
4619265 | Morgan et al. | Oct 1986 | A |
4632122 | Johansson et al. | Dec 1986 | A |
4679572 | Baker, Jr. | Jul 1987 | A |
4698848 | Buckley | Oct 1987 | A |
4729377 | Granek et al. | Mar 1988 | A |
4823796 | Benson | Apr 1989 | A |
4889131 | Salem et al. | Dec 1989 | A |
4926879 | Sevrain et al. | May 1990 | A |
4928690 | Heilman et al. | May 1990 | A |
4938231 | Milijasevic et al. | Jul 1990 | A |
4978926 | Zerod et al. | Dec 1990 | A |
4991217 | Garrett et al. | Feb 1991 | A |
5000189 | Throne et al. | Mar 1991 | A |
5007427 | Suzuki et al. | Apr 1991 | A |
5062834 | Gross et al. | Nov 1991 | A |
5078134 | Heilman et al. | Jan 1992 | A |
5097830 | Eikefjord et al. | Mar 1992 | A |
5224479 | Sekine | Jul 1993 | A |
5225763 | Krohn et al. | Jul 1993 | A |
5306956 | Ikeda et al. | Apr 1994 | A |
5342404 | Alt et al. | Aug 1994 | A |
5348008 | Bornn et al. | Sep 1994 | A |
5357696 | Gray et al. | Oct 1994 | A |
5361412 | Perry | Nov 1994 | A |
5365932 | Greenhut | Nov 1994 | A |
5371692 | Draeger et al. | Dec 1994 | A |
5381798 | Burrows | Jan 1995 | A |
5405361 | Persson | Apr 1995 | A |
5413262 | Dewire et al. | May 1995 | A |
5433737 | Aimone | Jul 1995 | A |
5443494 | Paolizzi et al. | Aug 1995 | A |
5470341 | Kuehn et al. | Nov 1995 | A |
5544661 | Davis et al. | Aug 1996 | A |
5558098 | Fain | Sep 1996 | A |
5558640 | Pfeiler et al. | Sep 1996 | A |
5601612 | Gliner et al. | Feb 1997 | A |
5606242 | Hull et al. | Feb 1997 | A |
5607454 | Cameron et al. | Mar 1997 | A |
5611085 | Rasmussen | Mar 1997 | A |
5619117 | Koenck | Apr 1997 | A |
5625291 | Brink et al. | Apr 1997 | A |
5662689 | Elsberry et al. | Sep 1997 | A |
5701894 | Cherry et al. | Dec 1997 | A |
5708978 | Johnsrud | Jan 1998 | A |
5718242 | McClure et al. | Feb 1998 | A |
5721482 | Benvegar et al. | Feb 1998 | A |
5724025 | Tavori | Mar 1998 | A |
5730143 | Schwarzberg | Mar 1998 | A |
5738102 | Lemelson | Apr 1998 | A |
5741306 | Glegyak et al. | Apr 1998 | A |
5758366 | Wilson | Jun 1998 | A |
5758443 | Pedrazzini | Jun 1998 | A |
5772604 | Langberg et al. | Jun 1998 | A |
5792190 | Olson et al. | Aug 1998 | A |
5824017 | Sullivan et al. | Oct 1998 | A |
5827196 | Yeo | Oct 1998 | A |
5830236 | Mouchawar et al. | Nov 1998 | A |
5833714 | Loeb | Nov 1998 | A |
5887978 | Lunghofer et al. | Mar 1999 | A |
5924979 | Swedlow et al. | Jul 1999 | A |
5929601 | Kaib et al. | Jul 1999 | A |
5944669 | Kaib | Aug 1999 | A |
6016445 | Baura | Jan 2000 | A |
6045503 | Grabner et al. | Apr 2000 | A |
6047203 | Sackner et al. | Apr 2000 | A |
6065154 | Hulings et al. | May 2000 | A |
6097982 | Glegyak et al. | Aug 2000 | A |
6097987 | Milani | Aug 2000 | A |
6148233 | Owen et al. | Nov 2000 | A |
6169387 | Kaib | Jan 2001 | B1 |
6169397 | Steinbach et al. | Jan 2001 | B1 |
6178343 | Bindszus et al. | Jan 2001 | B1 |
6208896 | Mulhauser | Mar 2001 | B1 |
6253099 | Oskin et al. | Jun 2001 | B1 |
6280461 | Glegyak et al. | Aug 2001 | B1 |
6336900 | Alleckson et al. | Jan 2002 | B1 |
6374138 | Owen et al. | Apr 2002 | B1 |
6390996 | Halperin et al. | May 2002 | B1 |
6406426 | Reuss et al. | Jun 2002 | B1 |
6418346 | Nelson et al. | Jul 2002 | B1 |
6442433 | Linberg | Aug 2002 | B1 |
6546285 | Owen et al. | Apr 2003 | B1 |
6681003 | Linder et al. | Jan 2004 | B2 |
6687523 | Jayaramen et al. | Feb 2004 | B1 |
6690969 | Bystrom et al. | Feb 2004 | B2 |
6694191 | Starkweather et al. | Feb 2004 | B2 |
6804554 | Ujhelyi et al. | Oct 2004 | B2 |
6827695 | Palazzolo et al. | Dec 2004 | B2 |
6865413 | Halperin et al. | Mar 2005 | B2 |
6889078 | Struble et al. | May 2005 | B2 |
6889079 | Bocek et al. | May 2005 | B2 |
6908437 | Bardy | Jun 2005 | B2 |
6925330 | Kleine | Aug 2005 | B2 |
6961612 | Elghazzawi et al. | Nov 2005 | B2 |
6990373 | Jayne et al. | Jan 2006 | B2 |
7130690 | Rueter et al. | Oct 2006 | B2 |
7149579 | Koh et al. | Dec 2006 | B1 |
7220235 | Geheb et al. | May 2007 | B2 |
7295871 | Halperin et al. | Nov 2007 | B2 |
7340296 | Stahmann et al. | Mar 2008 | B2 |
7453354 | Reiter et al. | Nov 2008 | B2 |
7476206 | Palazzolo et al. | Jan 2009 | B2 |
7488293 | Marcovecchio et al. | Feb 2009 | B2 |
7534212 | Baker, Jr. | May 2009 | B2 |
7712373 | Nagle et al. | May 2010 | B2 |
7831303 | Rueter et al. | Nov 2010 | B2 |
7974689 | Volpe et al. | Jul 2011 | B2 |
7991460 | Fischell et al. | Aug 2011 | B2 |
8121683 | Bucher et al. | Feb 2012 | B2 |
8140154 | Donnelly et al. | Mar 2012 | B2 |
8271082 | Donnelly et al. | Sep 2012 | B2 |
8369944 | Macho et al. | Feb 2013 | B2 |
8406842 | Kaib et al. | Mar 2013 | B2 |
8644925 | Volpe et al. | Feb 2014 | B2 |
8649861 | Donnelly et al. | Feb 2014 | B2 |
8676313 | Volpe et al. | Mar 2014 | B2 |
8706215 | Kaib et al. | Apr 2014 | B2 |
8774917 | Macho et al. | Jul 2014 | B2 |
8880196 | Kaid | Nov 2014 | B2 |
8897860 | Volpe et al. | Nov 2014 | B2 |
8904214 | Volpe et al. | Dec 2014 | B2 |
9161723 | Rodriguez-Llorente et al. | Oct 2015 | B2 |
9283399 | Donnelly et al. | Mar 2016 | B2 |
20010031991 | Russial | Oct 2001 | A1 |
20020077689 | Kirkland | Jun 2002 | A1 |
20030004547 | Owen et al. | Jan 2003 | A1 |
20030032988 | Fincke | Feb 2003 | A1 |
20030095648 | Kaib et al. | May 2003 | A1 |
20030109904 | Silver et al. | Jun 2003 | A1 |
20030149462 | White et al. | Aug 2003 | A1 |
20030158593 | Heilman et al. | Aug 2003 | A1 |
20030174049 | Beigel et al. | Sep 2003 | A1 |
20030195567 | Jayne et al. | Oct 2003 | A1 |
20030212311 | Nova et al. | Nov 2003 | A1 |
20030216786 | Russial | Nov 2003 | A1 |
20040007970 | Ma et al. | Jan 2004 | A1 |
20040010294 | Kleine | Jan 2004 | A1 |
20040049233 | Edwards | Mar 2004 | A1 |
20040143297 | Ramsey | Jul 2004 | A1 |
20040162510 | Jayne et al. | Aug 2004 | A1 |
20040249419 | Chapman et al. | Dec 2004 | A1 |
20050049515 | Misczynski et al. | Mar 2005 | A1 |
20050049644 | Warren et al. | Mar 2005 | A1 |
20050131465 | Freeman et al. | Jun 2005 | A1 |
20050144043 | Holland et al. | Jun 2005 | A1 |
20050246199 | Futch | Nov 2005 | A1 |
20050283198 | Haubrich et al. | Dec 2005 | A1 |
20050288599 | MacAdam | Dec 2005 | A1 |
20060036292 | Smith et al. | Feb 2006 | A1 |
20060085049 | Cory et al. | Apr 2006 | A1 |
20060095091 | Drew | May 2006 | A1 |
20060178706 | Lisogurski et al. | Aug 2006 | A1 |
20060211934 | Hassonjee et al. | Sep 2006 | A1 |
20060220809 | Stigall et al. | Oct 2006 | A1 |
20060270952 | Freeman et al. | Nov 2006 | A1 |
20070016029 | Donaldson | Jan 2007 | A1 |
20070073120 | Li et al. | Mar 2007 | A1 |
20070118056 | Wang et al. | May 2007 | A1 |
20070129769 | Bourget et al. | Jun 2007 | A1 |
20070143864 | Cabana et al. | Jun 2007 | A1 |
20070161913 | Farrell et al. | Jul 2007 | A1 |
20070162390 | Pancholy et al. | Jul 2007 | A1 |
20070169364 | Townsend et al. | Jul 2007 | A1 |
20070197878 | Shklarski | Aug 2007 | A1 |
20070239214 | Cinbis | Oct 2007 | A1 |
20070239220 | Greenhut et al. | Oct 2007 | A1 |
20070265533 | Tran | Nov 2007 | A1 |
20070265671 | Roberts et al. | Nov 2007 | A1 |
20080004536 | Baxi et al. | Jan 2008 | A1 |
20080021532 | Kveen et al. | Jan 2008 | A1 |
20080030656 | Watson et al. | Feb 2008 | A1 |
20080033495 | Kumar | Feb 2008 | A1 |
20080045815 | Derchak et al. | Feb 2008 | A1 |
20080058884 | Matos | Mar 2008 | A1 |
20080097793 | Dicks et al. | Apr 2008 | A1 |
20080103402 | Stickney et al. | May 2008 | A1 |
20080167535 | Stivoric et al. | Jul 2008 | A1 |
20080177193 | Farringdon | Jul 2008 | A1 |
20080177341 | Bowers | Jul 2008 | A1 |
20080183090 | Farringdon et al. | Jul 2008 | A1 |
20080249591 | Gaw et al. | Oct 2008 | A1 |
20080281168 | Gibson | Nov 2008 | A1 |
20080287749 | Reuter | Nov 2008 | A1 |
20080294019 | Tran | Nov 2008 | A1 |
20080306560 | Macho et al. | Dec 2008 | A1 |
20080306562 | Donnelly et al. | Dec 2008 | A1 |
20080312520 | Rowlandson et al. | Dec 2008 | A1 |
20080312522 | Rowlandson et al. | Dec 2008 | A1 |
20080312709 | Volpe et al. | Dec 2008 | A1 |
20090018428 | Dias et al. | Jan 2009 | A1 |
20090066366 | Solomon | Mar 2009 | A1 |
20090073991 | Landrum et al. | Mar 2009 | A1 |
20090076336 | Mazar et al. | Mar 2009 | A1 |
20090076340 | Libbus et al. | Mar 2009 | A1 |
20090076341 | James et al. | Mar 2009 | A1 |
20090076342 | Amurthur et al. | Mar 2009 | A1 |
20090076343 | James et al. | Mar 2009 | A1 |
20090076344 | Libbus et al. | Mar 2009 | A1 |
20090076345 | Manicka et al. | Mar 2009 | A1 |
20090076346 | James et al. | Mar 2009 | A1 |
20090076348 | Manicka et al. | Mar 2009 | A1 |
20090076349 | Libbus et al. | Mar 2009 | A1 |
20090076350 | Bly et al. | Mar 2009 | A1 |
20090076363 | Bly et al. | Mar 2009 | A1 |
20090076364 | Libbus et al. | Mar 2009 | A1 |
20090076397 | Libbus et al. | Mar 2009 | A1 |
20090076405 | Amurthur et al. | Mar 2009 | A1 |
20090076410 | Libbus et al. | Mar 2009 | A1 |
20090076559 | Libbus et al. | Mar 2009 | A1 |
20090093687 | Telfort et al. | Apr 2009 | A1 |
20090118808 | Belacazar et al. | May 2009 | A1 |
20090138059 | Ouwerkerk | May 2009 | A1 |
20090146822 | Soliman | Jun 2009 | A1 |
20090212984 | Baker | Aug 2009 | A1 |
20090231124 | Klabunde et al. | Sep 2009 | A1 |
20090232286 | Hurwitz | Sep 2009 | A1 |
20090234410 | Libbus et al. | Sep 2009 | A1 |
20090264792 | Mazar | Oct 2009 | A1 |
20090275848 | Brockway et al. | Nov 2009 | A1 |
20090281394 | Russell et al. | Nov 2009 | A1 |
20090287120 | Ferren et al. | Nov 2009 | A1 |
20090292194 | Libbus et al. | Nov 2009 | A1 |
20090295326 | Daynes et al. | Dec 2009 | A1 |
20090307266 | Fleizach et al. | Dec 2009 | A1 |
20090312650 | Maile et al. | Dec 2009 | A1 |
20090318779 | Tran | Dec 2009 | A1 |
20100010559 | Zhang et al. | Jan 2010 | A1 |
20100052892 | Allen et al. | Mar 2010 | A1 |
20100052897 | Allen et al. | Mar 2010 | A1 |
20100056881 | Libbus et al. | Mar 2010 | A1 |
20100069735 | Berkner | Mar 2010 | A1 |
20100076513 | Warren et al. | Mar 2010 | A1 |
20100076533 | Dar et al. | Mar 2010 | A1 |
20100081962 | Hamaguchi et al. | Apr 2010 | A1 |
20100114243 | Nowak et al. | May 2010 | A1 |
20100152600 | Droitcour | Jun 2010 | A1 |
20100171611 | Gao et al. | Jul 2010 | A1 |
20100234716 | Engel | Sep 2010 | A1 |
20100241181 | Savage et al. | Sep 2010 | A1 |
20100295674 | Hsieh et al. | Nov 2010 | A1 |
20100298899 | Donnelly et al. | Nov 2010 | A1 |
20100305462 | Callas | Dec 2010 | A1 |
20100312297 | Volpe et al. | Dec 2010 | A1 |
20110015533 | Cox et al. | Jan 2011 | A1 |
20110022105 | Owen et al. | Jan 2011 | A9 |
20110093840 | Pynenburg et al. | Apr 2011 | A1 |
20110098765 | Patel | Apr 2011 | A1 |
20110170692 | Konrad et al. | Jul 2011 | A1 |
20110172550 | Martin et al. | Jul 2011 | A1 |
20110288604 | Kaib et al. | Nov 2011 | A1 |
20110288605 | Kaib et al. | Nov 2011 | A1 |
20120011382 | Volpe et al. | Jan 2012 | A1 |
20120016361 | White et al. | Jan 2012 | A1 |
20120053479 | Hopenfeld | Mar 2012 | A1 |
20120112903 | Kaib et al. | May 2012 | A1 |
20120146797 | Oskin et al. | Jun 2012 | A1 |
20120150008 | Kaib et al. | Jun 2012 | A1 |
20120158075 | Kaib et al. | Jun 2012 | A1 |
20120283794 | Kaib et al. | Nov 2012 | A1 |
20120289809 | Kaib et al. | Nov 2012 | A1 |
20120293323 | Kaib et al. | Nov 2012 | A1 |
20120302860 | Volpe et al. | Nov 2012 | A1 |
20130013014 | Donnelly et al. | Jan 2013 | A1 |
20130060149 | Song et al. | Mar 2013 | A1 |
20130085538 | Volpe et al. | Apr 2013 | A1 |
20130144355 | Macho et al. | Jun 2013 | A1 |
20130218252 | Kaib et al. | Aug 2013 | A1 |
20130231711 | Kaib | Sep 2013 | A1 |
20130324868 | Kaib et al. | Dec 2013 | A1 |
20130325078 | Whiting et al. | Dec 2013 | A1 |
20130325096 | Dupelle et al. | Dec 2013 | A1 |
20140163334 | Volpe et al. | Jun 2014 | A1 |
20140206974 | Volpe et al. | Jul 2014 | A1 |
20140277243 | Maskara et al. | Sep 2014 | A1 |
20140303680 | Donnelly et al. | Oct 2014 | A1 |
20140324112 | Macho et al. | Oct 2014 | A1 |
20150035654 | Kaib et al. | Feb 2015 | A1 |
20150039042 | Amsler et al. | Feb 2015 | A1 |
20150039053 | Kaib et al. | Feb 2015 | A1 |
20150080699 | Kaib et al. | Mar 2015 | A1 |
20150224330 | Kaib et al. | Aug 2015 | A1 |
Number | Date | Country |
---|---|---|
396048 | Nov 1990 | EP |
0295497 | Sep 1993 | EP |
0335356 | Mar 1996 | EP |
0707825 | Apr 1996 | EP |
0761255 | Mar 1997 | EP |
1455640 | Jan 2008 | EP |
1720446 | Jul 2010 | EP |
5115450 | May 1993 | JP |
2002-514107 | May 2002 | JP |
2002200059 | Jul 2002 | JP |
2008-302228 | Dec 2008 | JP |
2008302225 | Dec 2008 | JP |
2009510631 | Mar 2009 | JP |
8304171 | Dec 1983 | WO |
1997022297 | Jun 1997 | WO |
1998039061 | Sep 1998 | WO |
1998043537 | Oct 1998 | WO |
1999059465 | Nov 1999 | WO |
2000002484 | Jan 2000 | WO |
2000030529 | Jun 2000 | WO |
2004054656 | Jul 2004 | WO |
2004067083 | Aug 2004 | WO |
2004078259 | Sep 2004 | WO |
2005082454 | Sep 2005 | WO |
2006050325 | May 2006 | WO |
2007019325 | Feb 2007 | WO |
2009034506 | Mar 2009 | WO |
2009122277 | Oct 2009 | WO |
2010025432 | Mar 2010 | WO |
2010077997 | Jul 2010 | WO |
2012006524 | Jan 2012 | WO |
2013130957 | Sep 2013 | WO |
2014097035 | Jun 2014 | WO |
Entry |
---|
International Search Report from corresponding International Application No. PCT/US2012/030433, dated Jul. 5, 2012. |
Association for the Advancement of Medical Instrumentation, ANSI/AAMI DF80:2003 Medical Electrical Equipment—Part 2-4: Particular Requirements for the Safety of Cardiac Defibrillators (including Automated External Defibrillators) 2004, ISBN 1-57020-210-9; abstract; p. vi; p. 50, section 107.1.2. |
Zoll Medical Corporation, LifeVest Model WCD 3000 Operator's Manual, Pittsburgh, PA. |
“ATS Statement: Guidelines for the Six-Minute Walk Test”, American Journal of Respiratory and Critical Care Medicine, 2002, pp. 111-117, vol. 166, American Thoracic Society, available at <http://ajrccm.atsjournals.org/cgi/content/full/166/1/111>. |
Debock et al., “Captopril Treatment of Chronic Heart Failure in the Very Old”, J. Gerontol, 1994, 49: M148-M152. |
http://web.archive.org/web/20030427001846/http://www.lifecor.com/imagelib/imageproduct.asp Published by LifeCor, Inc., 2002, on a webpage owned by LifeCor, Inc. |
O'Keeffe et al., “Reproducability and Responsiveness of Quality of Life Assessment and Six Minute Walk Test in Elderly Heart Failure Patients”, Heart, 1998, pp. 377-382, 80. |
Number | Date | Country | |
---|---|---|---|
20160317059 A1 | Nov 2016 | US |
Number | Date | Country | |
---|---|---|---|
61467599 | Mar 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14536189 | Nov 2014 | US |
Child | 15205584 | US | |
Parent | 13428329 | Mar 2012 | US |
Child | 14536189 | US |